GlassScriptPhysician profile
Catherine A Earl
NPI 1942626874
$14,999.05
in general payments reported to CMS, 2019-2025
49 companies · $3,048 in 2025
The $3,048 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,573 · 2022: $3,063 · 2023: $3,026 · 2024: $3,290 · 2025: $3,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,362.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,284.21 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $2,181.35 | 2021-2025 | |
| Lilly USA, LLC | $1,163.19 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,005.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $849.71 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $740.61 | 2021-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $636.14 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $529.84 | 2021-2025 | |
| Amarin Pharma, INC. | $519.98 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $485.78 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $460.62 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.93 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $403.26 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.49 | 2021-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $320.55 | 2021-2024 | Livalo, Seglentis |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.